 Allena Pharmaceuticals, Inc. ALNA, a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 7,317,074 shares of the Companys common stock, at a purchase price of 2.05 per share, in a registered direct offering priced at-the-market under Nasdaq rules. The gross proceeds to the Company from this offering are expected to be approximately 15.0 million, before deducting the placement agents fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for general working capital purposes. 